Topic | Publication type | Reference to publication |
Risk vs. benefit: >100:1 Uncirc’d affected: 1 in 3 | Risk-benefit analysis | Morris et al. (2006) [18] |
Risk vs. benefit: >100:1 Uncirc’d affected: 1 in 3 | Risk-benefit analysis | Morris (2007) [72] |
Risk vs. benefit: >100:1 Uncirc’d affected: 1 in 2 | Risk-benefit analysis | Morris et al. (2012) [73] |
Risk vs. benefit: >100:1 Uncirc’d affected: 1 in 2 | Risk-benefit analysis | Morris et al. (2014) [96] |
Risk vs. benefit: >100:1 Uncirc’d affected: 1 in 1.5 | Risk-benefit analysis | Morris et al. (2016) [52] |
Risk vs. benefit: ~200:1 Uncirc’d affected: 1 in 1.3 | Risk-benefit analysis | Morris et al. (2017) [74] |
MC and lower oncogenic HPV OR 0.52 (95% CI 0.33 - 0.82) | Meta-analysis | Morris et al. (2011) [75] |
Phimosis and penile cancer risk OR 12.1 (95% CI 5.57 - 26.2) | Meta-analysis | Morris et al. (2011) [75] |
Balanitis and penile cancer risk OR 3.82 (95% CI 1.61 - 9.06) | Meta-analysis | Morris et al. (2011) [75] |
Smegma and penile cancer risk OR 3.04 (95% CI 1.29 - 7.16) | Meta-analysis | Morris et al. (2011) [75] |
MC and reduction in penile inflammatory skin conditions OR 0.32 (95% CI 0.20 - 0.52) | Meta-analysis | Morris et al. (2012) [76] Morris & Krieger (2017) [98] |
MC and meatal stenosis risk Risk 0.66% (95% CI 0.43 - 0.91) | Meta-analysis | Morris & Krieger (2017) [99] |
MC and lower lifetime UTI risk OR 0.27 (95% CI 0.085 - 0.87) | Systematic review and meta-analysis | Morris & Wiswell (2013) [77] |
MC and sexual function, sensitivity and sensation | Systematic review | Morris & Krieger (2013) [37] |
Country-specific and global Prevalence of MC | Systematic review | Morris et al. (2016) [79] [80] |
MC, benefits and risks | Systematic review | Morris et al. (2017) [74] |
MC and penile inflammatory skin conditions | Systematic review | Morris & Krieger (2017) [78] |
World first patent for use of PCR for viral (HPV) testing | Patents: US, Australia, Europe, Japan | Morris & Nightingale (1987) [100] |